IHC - BREAST HORMONE RECEPTOR AND PROGNOSTIC PANEL (ER, PR, HER2NEU, KI67)

IHC – Breast Hormone Receptor and Prognostic Panel

(ER, PR, HER2neu, Ki67)

The Breast Hormone Receptor and Prognostic Panel is a comprehensive immunohistochemistry (IHC) diagnostic test used for detailed evaluation of breast cancer tissue. This advanced panel analyzes four critical tumor markers:

• ER (Estrogen Receptor)
• PR (Progesterone Receptor)
• HER2neu (Human Epidermal Growth Factor Receptor 2)
• Ki67 (Cell Proliferation Marker)

These biomarkers provide essential information for breast cancer diagnosis, tumor classification, prognosis assessment, and personalized treatment planning.

The panel helps determine whether breast cancer cells depend on hormones for growth, whether HER2-targeted therapy may be effective, and how rapidly cancer cells are multiplying.

This test is performed on FFPE (Formalin-Fixed Paraffin-Embedded) breast tissue biopsy or surgical specimens using advanced antibody staining techniques. Expert oncopathologists examine the tissue microscopically to assess receptor positivity and tumor proliferation activity.

The results guide oncologists in selecting the most effective treatment options such as:

• Hormone therapy
• HER2-targeted therapy
• Chemotherapy
• Combination treatment plans

This panel is considered essential for modern breast cancer precision medicine.

Benefits of the Test

• Determines breast cancer subtype accurately
• Guides hormone therapy eligibility
• Identifies HER2-targeted treatment suitability
• Measures tumor growth rate
• Helps predict prognosis
• Supports personalized cancer treatment planning

Why Doctors Recommend This Test

Doctors commonly recommend this panel when:

• Breast cancer is newly diagnosed
• Tumor subtype classification is required
• Treatment planning depends on receptor status
• HER2-targeted therapy eligibility must be assessed
• Cancer aggressiveness evaluation is needed
• Recurrence risk assessment is required
• Biopsy diagnosis needs confirmation
• Personalized oncology treatment is essential

This test ensures evidence-based and individualized breast cancer management.

Preparation Before the Test

Preparation usually includes:

• Submission of FFPE breast tissue block or unstained slides
• Previous pathology reports
• Relevant imaging reports (mammogram, MRI, ultrasound)
• Proper tissue labeling and packaging
• Laboratory authorization documentation

No fasting or direct patient preparation is required.

Normal Reporting Time

The normal reporting time for the Breast Hormone Receptor Prognostic Panel is usually 5–7 working days, depending on tissue processing and interpretation complexity.

Who Should Take This Test?

This test is recommended for:

• Patients newly diagnosed with breast cancer
• Individuals requiring breast tumor classification
• Patients undergoing treatment planning
• Individuals requiring HER2 assessment
• Oncology patients under specialist care
• Patients needing advanced breast cancer prognosis evaluation

At Focus Diagnostics Hyderabad, advanced immunohistochemistry technology and expert breast oncopathology specialists ensure highly accurate ER, PR, HER2neu, and Ki67 reports for reliable diagnosis and personalized treatment planning.